Colorectal cancer (CRC) ranks as second most common cause of cancer-related deaths. The CRC management considerably improved in recent years, especially due to biological therapies such as bevacizumab. The lack of predictive or prognostic biomarkers remains one of the major disadvantages of using bevacizumab in the CRC management. We performed a prospective study to analyze the prognostic and predictive roles of three potential serum biomarkers (Cyclophilin A (CypA), copeptin and Tie2) investigated by ELISA in 56 patients with metastatic CRC undergoing bevacizumab and chemotherapy between May 2019 and September 2021 at baseline and after one and six months of therapy. We showed that low levels of CypA at baseline and after one month of treatment were associated with better overall survival (OS) (42 versus 24 months,p= 0.029 at baseline; 42 versus 25 months,p= 0.039 after one month). For copeptin and Tie2, Kaplan–Meier curves showed no correlation between these biomarkers and OS or progression-free survival. When adjusting for baseline and post-treatment factors, a multivariate Cox analysis showed that low values of CypA at baseline and after one month of treatment were independent prognostic factors for OS and correlated with a better prognosis in metastatic CRC patients.
结直肠癌（CRC）是癌症相关死亡的第二大常见原因。近年来，结直肠癌的治疗取得了显著进展，尤其是得益于贝伐珠单抗等生物疗法的应用。然而，缺乏预测性或预后性生物标志物仍然是贝伐珠单抗在结直肠癌治疗中的主要不足之一。我们进行了一项前瞻性研究，旨在分析三种潜在血清生物标志物（亲环蛋白A（CypA）、和肽素及Tie2）的预后和预测作用。研究采用ELISA法检测了56例转移性结直肠癌患者在接受贝伐珠单抗联合化疗期间（2019年5月至2021年9月）基线水平及治疗1个月和6个月后的血清样本。结果显示，基线及治疗1个月后CypA低水平与更好的总生存期（OS）相关（基线：42个月对比24个月，p=0.029；治疗1个月后：42个月对比25个月，p=0.039）。对于和肽素与Tie2，Kaplan-Meier曲线显示这些生物标志物与OS或无进展生存期无相关性。经基线及治疗后因素校正后，多变量Cox分析表明，基线及治疗1个月后CypA低水平是OS的独立预后因素，并与转移性结直肠癌患者更好的预后相关。
肿瘤(癌症)患者之家